Methods of modifying eukaryotic cells
CA 2438390 C · Owner: Regeneron Pharmaceuticals, Inc. · Inventors: Stevens, Sean; Karow, Margaret; Murphy, Andrew J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for engineering and utilizing large DNA vectors to target via , homologous recombination, and modify in any desirable fashion, endogenous , genes and chromosomal loci in eukarytoic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs are derived from fragments of , cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 15, 2002 and granted October 28, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 15, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 15, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.